These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. Weis M; Pehlivanli S; Meiser BM; von Scheidt W J Am Coll Cardiol; 2001 Sep; 38(3):814-8. PubMed ID: 11527639 [TBL] [Abstract][Full Text] [Related]
5. Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease. Undas A; Stepien E; Potaczek DP; Tracz W Atherosclerosis; 2009 Jun; 204(2):567-72. PubMed ID: 19027114 [TBL] [Abstract][Full Text] [Related]
6. Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Li Q; Wang D; Wang Y; Xu Q Transplant Proc; 2006 Nov; 38(9):2899-904. PubMed ID: 17112859 [TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. Weber C; Erl W; Weber KS; Weber PC J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917 [TBL] [Abstract][Full Text] [Related]
8. Statins for all. Neild GH Transplantation; 2000 May; 69(9):1767-8. PubMed ID: 10830204 [No Abstract] [Full Text] [Related]
9. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Bea F; Blessing E; Shelley MI; Shultz JM; Rosenfeld ME Atherosclerosis; 2003 Apr; 167(2):187-94. PubMed ID: 12818400 [TBL] [Abstract][Full Text] [Related]
10. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. Mehra MR; Uber PA; Vivekananthan K; Solis S; Scott RL; Park MH; Milani RV; Lavie CJ J Am Coll Cardiol; 2002 Nov; 40(9):1609-14. PubMed ID: 12427413 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. Keogh A; Macdonald P; Kaan A; Aboyoun C; Spratt P; Mundy J J Heart Lung Transplant; 2000 Jun; 19(6):529-37. PubMed ID: 10867332 [TBL] [Abstract][Full Text] [Related]
12. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Han KH; Ryu J; Hong KH; Ko J; Pak YK; Kim JB; Park SW; Kim JJ Circulation; 2005 Mar; 111(11):1439-47. PubMed ID: 15781755 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Ferro D; Basili S; Alessandri C; Cara D; Violi F Atherosclerosis; 2000 Mar; 149(1):111-6. PubMed ID: 10704621 [TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Wei JL; Cui HM; Ma CY Eur J Med Res; 2007 May; 12(5):216-21. PubMed ID: 17513194 [TBL] [Abstract][Full Text] [Related]
15. The effects of lipid-lowering agents on acute renal allograft rejection. Kasiske BL; Heim-Duthoy KL; Singer GG; Watschinger B; Germain MJ; Bastani B Transplantation; 2001 Jul; 72(2):223-7. PubMed ID: 11477342 [TBL] [Abstract][Full Text] [Related]
16. Strategies for minimizing hyperlipidemia after cardiac transplantation. Kirklin JK; Benza RL; Rayburn BK; McGiffin DC Am J Cardiovasc Drugs; 2002; 2(6):377-87. PubMed ID: 14727953 [TBL] [Abstract][Full Text] [Related]
17. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Undas A; Brummel KE; Musial J; Mann KG; Szczeklik A Circulation; 2001 May; 103(18):2248-53. PubMed ID: 11342472 [TBL] [Abstract][Full Text] [Related]
18. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Waehre T; Damås JK; Gullestad L; Holm AM; Pedersen TR; Arnesen KE; Torsvik H; Frøland SS; Semb AG; Aukrust P J Am Coll Cardiol; 2003 May; 41(9):1460-7. PubMed ID: 12742282 [TBL] [Abstract][Full Text] [Related]